Loading...

KYTX KYVERNA THERAPEUTICS INC Product Launches 8-K Filing

KYVR

KYTX

KYVERNA THERAPEUTICS INC

(KYTX)

2026 8-K

CFO Appointment

Business Update Issued

Management Change

Positive Trial Results

Positive Trial Results

Positive Clinical Data

Quarterly Earnings Update

Board Appointments

Management Change

Management Change

Stock Offering Details

Positive Data Release

Positive Trial Results

Business Update

Loan Agreement Funded

Positive Trial Results

Positive Data Release

Financial Statements

Stock Sale Agreement

Financial Results

Management Appointment

Strategic Priorities

Management Change

Financial Update

Director Appointment

Management Changes

External Links:

Kyverna Therapeutics, Inc. announced positive long-term follow-up data from its Phase 2 trial of miv-cel for generalized myasthenia gravis on April 20, 2026, and positive primary results from the KYSA-8 trial for stiff person syndrome on April 21, 2026. They will host a conference call on April 22, 2026, to discuss these results.

AI Assistant

KYVERNA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.